Reduced chemo plus immunotherapy vs immunotherapy alone for older lung cancer patients
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a reduced dose of chemotherapy plus an immunotherapy drug (Cemiplimab) works better than Cemiplimab alone for older or frail patients with advanced lung cancer whose PD-L1 level is below 50%. It aims to find a gentler but effective treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older.
- You have been diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) that has not spread to the brain or is well-controlled if it has.
- Your cancer’s PD-L1 level is less than 50% (a test from your tumor).
- You have not had any prior chemotherapy or immunotherapy for your advanced lung cancer.
- You are considered frail or not fit for full-dose chemotherapy, based on a simple health screening test (G8 score) or your doctor’s judgment.
- You do not have certain genetic mutations (EGFR, ALK, etc.) in your cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
This trial tests whether adding an immunotherapy drug called cemiplimab to chemotherapy before a shorter course of radiation helps older or less fit patients with stage III lung cancer. It aims to improve treatment results while being more manageable for patients who might not tolerate standard therapies.
This trial tests a new way of giving chemotherapy and an immunotherapy drug (cemiplimab) before surgery for lung cancer that has a high PD-L1 level. The goal is to see if a shorter or adjusted course can shrink the tumor and improve outcomes while reducing side effects.
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
This study compares getting both chemotherapy and immunotherapy versus immunotherapy alone for older adults with advanced lung cancer. The goal is to see which approach is more effective and tolerable for people aged 70 and older.
This trial tests a combination of chemotherapy and immunotherapy for people 65 or older with metastatic non-small cell lung cancer that has not been treated before and expresses PD-L1. It aims to see if this treatment can help control the cancer.
Hear when a new Metastatic NSCLC - Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.